As has been shown, there are many potential benefits for the use of selective and non-selective NSAIDS in all aspects of breast cancer chemoprevention, along with treatment benefits in metastatic disease in combination with aromatase inhibitors. Here, CYP19A1 is linked to metastatic neoplasm.